Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting

Kerina Duri,Privilege Tendai Munjoma,Hope Mataramvura,Arthur John Mazhandu,Panashe Chandiwana,Tarisai Marere,Felicity Zvanyadza Gumbo,Lovemore Ronald Mazengera
DOI: https://doi.org/10.1186/s12879-023-08523-2
IF: 3.7
2023-10-29
BMC Infectious Diseases
Abstract:Despite the availability of an effective vaccine, chronic hepatitis B virus (HBV) infections remain a major cause of liver cirrhosis and hepatocellular carcinoma. HBV burden in pregnancy, risk factors and the timing of mother to child transmission remain poorly described especially during this era of lifelong use of Tenofovir/Lamivudine/Efavirenz as firstline for HIV treatment. We aimed to determine the burden of HBV in pregnancy and infants receiving their first dose of HBV vaccine 6 weeks after birth in a high HIV-prevalence setting.
infectious diseases
What problem does this paper attempt to address?